Spreading of Post COVID-19 Disease „Black Fungus“ in India – TIEFENBACHER GROUP supports with Posaconazole Tablets

Black Fungus (Mucormycosis) is dramatically spreading in India connected to the extensive 2nd COVID-19 wave. The highly life-threatening disease usually occurs as a rare disease in immunocompromised patients. However, many patients who have survived their COVID-19 infection with the help of external oxygen support are now affected by black fungus. Physicians in India believe that an inadequate oxygen supply of COVID-19 patients may be the reason for this dangerous development.

With Posaconazole tablets Tiefenbacher produces one of the most effective treatments against Black Fungus and is now supporting India to push back this disease fast. “When we heard about the problems with Black Fungus in India we directly decided to change our production plans and produce as fast as possible Posaconazole tablets for India. We hope to be able to help as many Black Fungus patients as fast as possible.” says Oliver Schrader, Joint Managing Director of TIEFENBACHER GROUP.


After more than five years in operation, TIEFENBACHER GROUP will transfer its medical device business into a new stand-alone company: TIEFENBACHER MEDICAL DEVICES.

The launch follows TIEFENBACHER GROUP´s strategy to offer better patient therapies by combining established drug-based medicines with medical devices & digital health. TIEFENBACHER MEDICAL DEVICES is focused on medical devices for respiratory treatments and multiple other innovative drug-device combination products for individualized treatments in globally relevant disease areas.

Please have a look at our Website: www.tiefenbachergroup.com/medical-device/

TIEFENBACHER MEDICAL DEVICES is developing medical devices as part of combination products and offering eHealth solutions where relevant. We leverage the full potential during drug-device combination product developments and keep people safe and healthy by maximizing treatment outcomes while minimizing healthcare spends. Driven by patient demands, we are managing the entire innovative process from concept to market entry and create healthcare opportunities across the globe as well as accelerating routes to market.

For further information around medical devices or other worldwide eHealth solutions please contact TIEFENBACHER MEDICAL DEVICES: info@aet.eu

TIEFENBACHER GROUP plays an active role in the fast changing and innovative ecosystem of the pharmaceutical industry and healthcare. Please visit us on: www.tiefenbachergroup.com


We at TIEFENBACHER API + INGREDIENTS are committed to drive green chemistry in the pharmaceutical raw material industry. Enviero Progesterone is an Active Pharmaceutical Ingredient (API) and the first molecule from TIEFENBACHER API + INGREDIENTS’ green-chemistry program by providing the latest in lower environmental impact products for patients around the world. Green chemistry is understood to have minimal impacts on the environment and human health, and also to be cost-effective.

Enviero Progesterone is produced on a synthesis that reduces waste, greenhouse gas emissions, and the use of hazardous solvents. As a result, out of this synthesis the carbon footprint of the Progesterone manufacturing process is reduced by more than 70 percent and eliminating the use of metal catalysts. This product is manufactured via a proprietary bio-catalytical process based on plant sterols.
According to the U.S. Environmental Protection Agency (EPA), Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.
TIEFENBACHER API + INGREDIENTS has been cooperating with the US-based manufacturer for
decades and is proud to start offering green chemistry API´s to our valuable customers in the pharmaceutical industry in Europe.

Enviero Progesterone is immediately available – and our whole portfolio includes more than 600+ API´s to secure the healthcare industry with high-quality solutions along the whole API value chain.
For more information, please contact TIEFENBACHER API + INGREDIENTS: Axel Hinsch a.hinsch@tifi-api.eu
Or please visit us on our TIEFENBACHER API + INGREDIENTS Website: www.tiefenbacher-api.com

TIEFENBACHER PHARMACEUTICALS announces global launch of Teriflunomide making multiple sclerosis therapy more affordable and better available worldwide

TIEFENBACHER PHARMACEUTICALS, part of TIEFENBACHER GROUP, has successfully developed a global dossier for a generic version of Teriflunomide 7 mg and 14 mg film-coated tablets.

Teriflunomide is an important part of the therapy of multiple sclerosis and the global roll-out of the product in more than 40 countries will make this therapy more affordable and better available for the over 2,8 million patients worldwide.

The product was developed and is commercially produced at our Indian manufacturing site TIEFENBACHER LABORATORIES in Hyderabad and at Combino Pharm Ltd.

The formulation has successfully passed four bioequivalence studies against reference products from three different markets. The product is already approved in Australia, Canada, New Zealand, and the US. Additional filings in Europe, South America and South Africa are under preparation and will take place this year in line with data exclusivity expiry.

For further information please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

Disclaimer: Teriflunomide, which is subject to patent prosecution, is currently not offered or made available in countries where patents are in force.

AET Pharma US Inc. Announces Successful approval of generic Posaconazole by the Food and Drug Administration (FDA)

On 1st February 2021, AET Pharma US Inc, part of TIEFENBACHER GROUP, received FDA approval of the Abbreviated New Drug Application (ANDA) for Posaconazole 100 mg Delayed-Release Tablets. This is another milestone for TIEFENBACHER GROUP in further strengthening its product portfolio in the United States. The US launch of Posaconazole will proceed in close cooperation with our experienced distribution partner, Lupin Pharmaceuticals Inc. With the market entry of Posaconazole, we look forward to increasing availability and ensuring affordability of this treatment for American patients.

The product has been developed by and is manufactured at TIEFENBACHER LABORATORIES in Hyderabad, India, and has already been successfully launched in the European Union and in Australia. The registration dossier is currently under filing in several additional international markets.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com

TIEFENBACHER PHARMACEUTICALS Announces Global Launch Of Rivaroxaban

TIEFENBACHER PHARMACEUTICALS, part of Tiefenbacher Group, is pleased to announce the availability of a registration dossier for the generic of Rivaroxaban 2.5 mg, 10 mg, 15 mg and 20 mg film-coated tablets.
The product was developed at TIEFENBACHER LABORATORIES, Hyderabad. Commercial production for early markets is conducted outside of Europe. For European markets, the product will be manufactured at TIEFENBACHER GROUP facility on Cyprus.

The formulation has successfully passed fifteen global bioequivalence studies and six additional pivotal studies are currently under preparation. The registration dossier is currently approved in several EU markets via DCP and via national applications in CIS countries and in Canada.

The product has already been successfully launched in early markets and further markets will follow during the course of this year. The registration dossier is under filing in several additional international markets with a global roll out to follow in more than sixty markets throughout the world.

The market exclusivity and basic patent have already expired, while the SPC will expire in September 2023 in Europe.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com

Disclaimer: Rivaroxaban, which is subject to patent prosecution, is currently not offered or made available in countries where patents are in force.

International Brand Relaunch of Tiefenbacher Group

“We are very excited to launch the new Tiefenbacher Group website. It represents the fundamental changes which we have started in the recent years. We are on the move to drive important efficiencies in our supply chain and become a more and more innovative, patient-centered enterprise with a global pharmaceutical footprint.”

Oliver Schrader, Managing Director Tiefenbacher Group

Tiefenbacher Group and OnDosis enter a strategic partnership for game-changing integration of medicines and digital health

Tiefenbacher Group and OnDosis today announced the signing of an extensive co-development agreement for multiple products in the upcoming years. This collaboration strengthens both companies’ commitment to further develop and commercialize innovative products within individualized treatments and digital health, combining traditional drug-based medicines with digital therapeutics and intelligent dosing.